The Reds are likely to send Aroldis Chapman to the minors

0 Comments

Chapman small.jpgMark Sheldon of MLB.com says its almost certain that Aroldis Chapman is going to start the season in the minor leagues as his recent back spasms simply didn’t permit him to get in enough work in order to force his way into the competition for the fifth starter’s spot, which will be won by either Mike Leake or Travis Wood.

All of which is actually pretty good from the Reds’ perspective, as Champan’s contract has an incentive clause that transforms the $5 million he’d be owed for 2013 and 2014 into a bonus if he becomes arbitration-eligible after 2012. If he becomes arb-eligible after 2013, the $3 million he’d get for 2014 alone is a bonus. So, by delaying him until mid-to-late May the Reds will save the usual year’s worth of arbitration-derived salary, plus a couple of million on top of it. Which, if you’re the Reds, ain’t exactly hay.

As for the Reds’ fifth starter race, I don’t know much about either Mike Leake or Travis Wood, but I do like the line that Red Reporter dropped on Twitter last week: it’s hard to take a Leake when you’ve got Wood.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.